Pharma BD Deal Intelligence

AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd.

2024 · Licensing/Option · $1.7B · Complete

AbbVie and FutureGen announced exclusive global license agreement for FG-M701, a next-generation fully human anti-TL1A monoclonal antibody in preclinical development for IBD. FutureGen receives $150M upfront/near-term plus up to $1.56B in development, regulatory and commercial milestones and tiered royalties up to low-double digits. AbbVie assumes global dev/mfg/commercialization rights.

Key facts

• Announced Jun 13, 2024
• Deal value $1.7B
• Deal type Licensing/Option
• Therapeutic area Inflammatory bowel disease (IBD)
• Indications Inflammatory bowel disease (IBD)
• Key assets FG-M701 (next-generation anti-TL1A mAb)
• Mechanism Anti-TL1A monoclonal antibody (next-generation with potential for less frequent dosing)

← Browse all deals  ·  How we score deals